AUSTIN, Texas--(BUSINESS WIRE)--Asuragen, Inc., a molecular diagnostics company using genomics to drive better patient management, announced today that it has appointed Matthew McManus, M.D., Ph.D., President and CEO and expanded its senior commercial leadership.
Dr. McManus joins Asuragen with more than 20 years of clinical diagnostic leadership experience and was most recently Chief Executive Officer and President of PrimeraDx, Inc., a molecular diagnostics company marketing a novel, multiplexed, multi-modal, molecular diagnostics instrument for oncology, infectious disease, and genetic testing. He previously served as Head of Cleveland Clinic Laboratories and Chief Operating Officer of the Pathology and Laboratory Medicine Institute at the Cleveland Clinic. Dr. McManus received an MD and PhD from the University of Pennsylvania School of Medicine, MBA from Boston College and BA from the College of the Holy Cross.
“I am pleased to be joining Asuragen at such an important inflection point in their growth,” commented Dr. McManus. “This is a great opportunity to further build on best in class molecular diagnostic products and to extend that capability with pharma partners in supporting their companion diagnostic programs.”
“Matt’s strong scientific and diagnostic business experience, combined with his enthusiastic leadership, make him the right choice to take the reins of Asuragen at this exciting time,” said Matt Winkler, Chairman and founder of Asuragen. “The board and I also want to recognize the leadership provided by our outgoing President and CEO, Rollie Carlson, who built a strong foundation for our future growth.”
In addition to Dr. McManus, the Company has recently made key commercial additions to its senior leadership team. Darin Leigh has been named Senior Vice President of Commercial Operations, and Eric Lindquist has joined as Vice President of Business Development - Companion Diagnostics.
Mr. Leigh has over 23 years of experience in commercial operations within the life science and medical device industry. Prior to Asuragen, Mr. Leigh was Vice President of Global Commercial Operations with Luminex Corporation, where he was responsible for global expansion and integration of multiple acquisitions, while delivering consistent double-digit revenue growth. He also served in strategic marketing and sales roles at Abbott Laboratories, where he successfully launched global immunochemistry products and led several sales teams.
Mr. Lindquist has over 15 years of experience in the IVD, diagnostic instrumentation and clinical testing industries. He has held senior roles in business development, sales and marketing at HTG, Ventana/Roche, Apocell, Vysis/Abbott and Veridex. During his time in these positions he was responsible for closing a number of companion diagnostic agreements with Transgene, Merck, Clovis, and Bayer.
Asuragen is a molecular diagnostics company using genomics to drive better patient management in oncology and genetic diseases through world leading clinical testing solutions. The company uses a breadth of technologies and scientific talent to discover, develop and commercialize diagnostic products and clinical testing services with efficiency and flexibility both internally and its companion diagnostic partners. Today, Asuragen’s products, services and technologies drive countless patient management decisions across oncology, genetic disease and other molecular testing modalities. In the future, we envision the company’s development of molecular-based clinical diagnostics will help transform medicine by improving clinical outcomes and health economics. For more information, visit www.asuragen.com.